The σ4 isoform of apolipoprotein E (ApoE) has been proposed as a risk factor for Alzheimer’s disease (AD), while the possible role of the σ2 allele in AD is controversial. We have studied the ApoE genotype in 38 patients with early-onset AD (EOAD) and in 43 patients with late-onset AD (LOAD). In the EOAD group we observed a significant increase of σ4 allele frequency as compared with normal controls, while there was a more than 3-fold decrease of σ2 allele frequency that did not reach statistical significance. In the LOAD group we found a highly significant increase of σ4 allele frequency as compared with normal controls, while there was a significant decrease of σ2 allele frequency. In both the EOAD and LOAD groups, no significant difference was observed between σ4 carriers and σ4 noncarriers as for age at disease onset, disease duration, and Mini-Mental State score at observation. However, in both EOAD and LOAD groups a statistical trend towards a longer disease duration was observed in σ4 carriers. In both the EOAD and LOAD groups, disease severity was compared in σ4 carriers versus σ4 noncarriers by means of analyses of covariance, with disease duration as covariate. No significant difference between σ4 carriers and σ4 noncarriers was observed in both EOAD and LOAD. The results of the present study confirm that σ4 allele seems to be associated with an increased risk for sporadic AD, while the significant decrease of σ2 allele frequency in the LOAD group supports the hypothesis of a possible protective role of σ2 allele in AD.

Keywords:
Apolipoprotein E, Alzheimer’s disease
This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.